The Slovenian Health Insurance Institute (ZZZS) today added Agamree (vamorolone) to the list of drugs for the treatment of Duchenne muscular dystrophy in patients over the age of four. The drug is available only with a prescription and is for oral use. Treatment can only be started by a specialist doctor, and the costs will be covered by the Slovenian Health Insurance Fund.
The association made the following statement: Today is an important day for patients with Duchenne muscular dystrophy (DMD), because the Slovenian Health Insurance Institute (ZZZS) has added the drug Agamree to the list of drugs used for the treatment of Duchenne muscular dystrophy (DMD) in patients from the age of four.
The drug will be covered by the Slovenian Health Insurance Fund as of April 23, 2025.
The drug is available only by prescription and is for oral use. Treatment can only be started by a specialist.
